Genomic Vision raises €4 million
This article was originally published in Scrip
Executive Summary
Genomic Vision has secured €4 million to fund its in-house R&D, automation and strengthen its collaborative programmes with partners. The French drug discovery and diagnostics firm will use its nanotechnology for DNA analysis in cancer and acute diseases. Genomic's Molecular Combing technology tests the efficacy of lead compounds by studying DNA replication in proliferating cancer cells. The series B round included new investor Vesalius BioCapital and existing investor Societe Generale Asset Management Alternative Investments. Since its inception in 2004, Genomic has raised €6 million.
You may also be interested in...
AB Science lists on Euronext after reducing offer size
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen posts strong first-quarter sales but healthcare reform set to bite
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Tracleer drives growth for Actelion
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.